Monopar Therapeutics Inc. Lease, Cost
Monopar Therapeutics Inc. (MNPR) reported Lease, Cost of $28.37 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-12
- Monopar Therapeutics Inc. lease, cost for the quarter ending 2026-06-30 was $28.37K, a 48.24% increase year-over-year.
- Monopar Therapeutics Inc. lease, cost for the quarter ending 2026-03-31 was $27.50K, a 92.13% increase year-over-year.
- Monopar Therapeutics Inc. lease, cost for the quarter ending 2025-12-31 was $21.93K, a 62.89% increase year-over-year.
- Monopar Therapeutics Inc. lease, cost for the quarter ending 2025-09-30 was $21.46K, a 59.42% increase year-over-year.
- Monopar Therapeutics Inc. lease, cost for fiscal 2025 was $76.84K, a 32.29% increase from fiscal 2024.
- Monopar Therapeutics Inc. lease, cost for fiscal 2024 was $58.09K.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.37K 10-Q · filed 2026-08-12 | $55.87K 10-Q · filed 2026-08-12 | $77.80K derived: sum of 3 quarters · filed 2026-08-12 | $99.26K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $27.50K 10-Q · filed 2026-05-14 | $49.42K derived: sum of 2 quarters · filed 2026-05-14 | $70.89K derived: sum of 3 quarters · filed 2026-05-14 | $90.03K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $21.93K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $43.39K derived: sum of 2 quarters · filed 2026-03-27 | $62.53K derived: sum of 3 quarters · filed 2026-08-12 | $76.84K 10-K · filed 2026-03-27 |
| 2025-09-30 | $21.46K 10-Q · filed 2025-11-13 | $40.60K derived: sum of 2 quarters · filed 2026-08-12 | $54.91K 10-Q · filed 2025-11-13 | $68.38K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $19.14K 10-Q · filed 2026-08-12 | $33.45K 10-Q · filed 2026-08-12 | $46.91K derived: sum of 3 quarters · filed 2026-08-12 | $60.38K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $14.31K 10-Q · filed 2026-05-14 | $27.77K derived: sum of 2 quarters · filed 2026-05-14 | $41.24K derived: sum of 3 quarters · filed 2026-05-14 | $54.70K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $13.46K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $26.92K derived: sum of 2 quarters · filed 2026-03-27 | $40.39K derived: sum of 3 quarters · filed 2026-03-27 | $58.09K 10-K · filed 2026-03-27 |
| 2024-09-30 | $13.46K 10-Q · filed 2025-11-13 | $26.92K derived: sum of 2 quarters · filed 2025-11-13 | $44.62K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $13.46K 10-Q · filed 2025-08-12 | $31.16K 10-Q · filed 2025-08-12 | ||
| 2022-03-31 | $11.08K 10-Q · filed 2022-05-12 | |||
| 2021-03-31 | $13.46K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |